Joe Newman, Ph.D.

Dr. Joe Newman has over 20 years of experience leading and supporting all stages of drug development, from lead optimization through to clinical development. Prior to joining Omega, Joe was Vice President of Early Development at Zikani Therapeutics, where he successfully transitioned the company’s focus from infectious diseases to oncology and rare diseases.
 
Prior to Zikani, he was the head of Biology at Tetraphase Therapeutics, leading the NDA and MAA submissions for Xerava®. Before that, Dr. Newman spent ten years at AstraZeneca in various roles supporting early development and IND submissions, including IND-enabling packages for Xacduro® and Zoliflodacin.
Dr. Newman received his undergraduate degree in Biology from the University of Delaware, his Ph.D. in Molecular Microbiology from the University of Rhode Island and completed fellowships at Tufts Medical School and MIT.